Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Extremely low viral reservoir in treated chronically HIV-1-infected individuals.
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.
A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights.
Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection.
Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients.
HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic.
Production of HIV-1-based virus-like particles for vaccination: achievements and limits.
CD4 recovery is associated with genetic variation in IFNγ and IL19 genes.